Head-to-Head

Immunovant, Inc. Common Stock vs. Moderna, Inc. Common Stock

IMVT

Immunovant, Inc. Common Stock

$37.66 +0.80%

VS MRNA

Moderna, Inc. Common Stock

$155.01 -1.94%

Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 2 compared factors.

Size & Scale

IMVTMRNA
Market Cap $7.72 billion $63.11 billion
Revenue (TTM) — $2.23 billion
Net Income (TTM) — $-3,151,000,000

MRNA leads on 1 of 1 size & scale factors.

Valuation

IMVTMRNA
Price / Book — 9.33
Price / Sales — 28.32

IMVT and MRNA split the valuation factors evenly.

Profitability

IMVTMRNA
Net Margin — -141.43%
Return on Equity — -46.61%

IMVT and MRNA split the profitability factors evenly.

Risk & Sentiment

IMVTMRNA
Short Interest 0.15% 0.01%

MRNA leads on 1 of 1 risk & sentiment factors.

Dig deeper: IMVT overview, IMVT financials, MRNA overview, MRNA financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.